| Cell capture structures | Targeted cells | Carrier medium and control cells | Target cell recovery rate | Capture purity
|
| Four successively narrower polyurethane channels | Human neuroblastoma cells | Human whole blood or isolated mononuclear cells in PBS | NA | NA |
| Glass based pool and dam structure | Human lung cancer cells of SPC-A- | Human blood from healthy donors (106 RBCs and 2 × 105 cancer cells) | 99.9% | NA |
| One-layer parylene-C membrane micro-filters | Human prostate cancer cells of LNCaP | Human blood samples from healthy donors (50 - 500 cell per ml) | 89.5% ± 9.5% | NA |
| One-layer parylene-C membrane micro-filter | Human breast cancer cells of MCF-7, SK-Br-3, and MDA-231, bladder cancer cells of J82, T24 andRT4 and prostate cancer cells of LNCaP | Human blood samples from healthy donors (5 cells per ml) | 96.5% (≥1 cells) and 64% (≥3 cells) | NA |
| One-layer parylene-C membrane micro-filter | CTCs | Blood samples from patients with metastatic prostate, breast, colon, or bladder cancer | CTC identification in 51 of 57 patient samples | NA |
| 3D parylene-C membrane micro-filters | Human prostate cancer cells of LNCaP and breast cancer cells of MCF-7 | Blood samples from health donors (~3 MCF-7 and ~100 LNCaP cells per ml) | 86.5% ± 5.3% | NA |
| PDMS based crescent shaped isolation wells | Human breast and cancer cells of MCF-7 and MDA-231, colon cancer cells of HT-29 | Blood samples from healthy donors (100 cancer cells per ml) | >80% | >80% |
| PDMS based crescent shaped isolation well | Human breast cancer cells of MCF-7 and MDA-231, gastric cancer cells of AGS and N87, hepatocellular cancer cells of HepG2 and HuH7, tongue cancer cells of CAL27 and pharynx cancer cells of FADU | PBS and whole blood samples from healthy donors (100 cancer cells per ml) | ~80% | Mean value of 89% |
| PDMS based crescent shaped isolation wells | CTCs | Blood samples from patients with metastatic lung cancer | CTC identification in 5 of 5 patient samples | Mean value of 83% |
| Size-selective micro-cavity arrays made of nickel | Human lung cancer cells of NCI-H358, breast cancer cells of MCF-7, gastric cancer cells of AGS and SNU-1, and colon cancer cells of SW620 | Blood samples from healthy donors (10 - 100 cancer cells per ml) | >80% | NA |
| PDMS based dam structures + lectin cocanavalin A | Human leukemic cells of K562 | Blood from healthy mice (106 RBCs and 2 × 105 K562 cells) | 84% | NA |
| Polyurethane-methacrylate based lateral micro-filters with arrays of pillars | Human breast cancer cells of MCF-7 (fixed and unfixed) | Blood samples from healthy donors | ~90% (fixed cancer cells) and~50% (unfixed cells | NA |
| Inertial flow in spiral micro-channels made of PDMS | Human neuroblastoma cells ofSH-SY5Y and rat glioma cells of C6 | PCB | ~80% | NA |
| PDMS based expansion- contraction reservoirs to produce micro-vortices | Human cervical cancer cells of HeLa and breast cancer cells of MCF-7 | Blood samples containing leukocytes only (1:100 of cancer cells to leukocytes) | ~23% (MCF-7) and~10% (HeLa) | 7.1-fold enrichment for MCF-7 and 5.5-fold |
| PDMS based high aspect ratio rectangular micro-channels patterned with a contraction- expansion array | Human breast cancer cells of MCF-7 | PBS and blood samples (500 MCF-7 cells per ml) | >90% (MCF-7 in PBS) and ~80% (MCF-7 in blood samples | 3.3 × 105-fold enrichment over RBCs and 1.2 × 104-fold enrichment over leukocytes |